Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Defective regulatory and effector T cell functions in patients with FOXP3 mutations
Rosa Bacchetta, … , Megan K. Levings, Maria Grazia Roncarolo
Rosa Bacchetta, … , Megan K. Levings, Maria Grazia Roncarolo
Published June 1, 2006
Citation Information: J Clin Invest. 2006;116(6):1713-1722. https://doi.org/10.1172/JCI25112.
View: Text | PDF
Research Article Immunology

Defective regulatory and effector T cell functions in patients with FOXP3 mutations

  • Text
  • PDF
Abstract

The autoimmune disease immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) is caused by mutations in the forkhead box protein P3 (FOXP3) gene. In the mouse model of FOXP3 deficiency, the lack of CD4+CD25+ Tregs is responsible for lethal autoimmunity, indicating that FOXP3 is required for the differentiation of this Treg subset. We show that the number and phenotype of CD4+CD25+ T cells from IPEX patients are comparable to those of normal donors. CD4+CD25high T cells from IPEX patients who express FOXP3 protein suppressed the in vitro proliferation of effector T cells from normal donors, when activated by “weak” TCR stimuli. In contrast, the suppressive function of CD4+CD25high T cells from IPEX patients who do not express FOXP3 protein was profoundly impaired. Importantly, CD4+CD25high T cells from either FOXP3+ or FOXP3– IPEX patients showed altered suppression toward autologous effector T cells. Interestingly, IL-2 and IFN-γ production by PBMCs from IPEX patients was significantly decreased. These findings indicate that FOXP3 mutations in IPEX patients result in heterogeneous biological abnormalities, leading not necessarily to a lack of differentiation of CD4+CD25high Tregs but rather to a dysfunction in these cells and in effector T cells.

Authors

Rosa Bacchetta, Laura Passerini, Eleonora Gambineri, Minyue Dai, Sarah E. Allan, Lucia Perroni, Franca Dagna-Bricarelli, Claudia Sartirana, Susanne Matthes-Martin, Anita Lawitschka, Chiara Azzari, Steven F. Ziegler, Megan K. Levings, Maria Grazia Roncarolo

×

Figure 8

Cytokine production by PBMCs isolated from IPEX patients: determination in cell culture supernatants.

Options: View larger image (or click on image) Download as PowerPoint
Cytokine production by PBMCs isolated from IPEX patients: determination ...
PBMCs were stimulated with immobilized anti-CD3 mAb (10 μg/ml) and soluble anti-CD28 mAb (1 μg/ml) (A) or with TPA and ionomycin (B). Supernatants were collected after 12 (IL-2) or 48 hours (all other cytokines), and cytokine concentrations were determined by cytometric bead array (see Methods for details). The values obtained in patient 1 (n = 2 independent determinations) and patient 2 (n = 4 independent determinations) were compared with those obtained in a cohort of age-matched NDs (n = 15) analyzed in parallel for statistical analysis. One single determination was performed in patients 2bis and 3.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts